Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:423  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 


 
   Table of Contents     
EDITORIAL  
Year : 2020  |  Volume : 12  |  Issue : 2  |  Page : 39-43
State of the globe: The trials and tribulations of the COVID-19 pandemic: Separated but together, telemedicine revolution, frontline struggle against “Silent Hypoxia,” the relentless search for novel therapeutics and vaccines, and the daunting prospect of “COVIFLU”


1 Department of Medicine, IGMC, Shimla, Himachal Pradesh, India
2 Department of Emergency Medicine, Sarasota Memorial Hospital, Sarasota, Florida, USA
3 Department of Internal Medicine, St. Luke's University Health Network, Richard A. Anderson Campus, Easton, Pennsylvania, USA
4 Department of Family Medicine, St. Luke's University Health Network, Richard A. Anderson Campus, Easton, Pennsylvania, USA
5 Department of Research and Innovation, St. Luke's University Health Network, University Hospital, Bethlehem, Pennsylvania, USA

Click here for correspondence address and email

Date of Submission23-Apr-2020
Date of Acceptance30-Apr-2020
Date of Web Publication22-May-2020
 

How to cite this article:
Chauhan V, Galwankar SC, Yellapu V, Perez-Figueroa IJ, Stawicki SP. State of the globe: The trials and tribulations of the COVID-19 pandemic: Separated but together, telemedicine revolution, frontline struggle against “Silent Hypoxia,” the relentless search for novel therapeutics and vaccines, and the daunting prospect of “COVIFLU”. J Global Infect Dis 2020;12:39-43

How to cite this URL:
Chauhan V, Galwankar SC, Yellapu V, Perez-Figueroa IJ, Stawicki SP. State of the globe: The trials and tribulations of the COVID-19 pandemic: Separated but together, telemedicine revolution, frontline struggle against “Silent Hypoxia,” the relentless search for novel therapeutics and vaccines, and the daunting prospect of “COVIFLU”. J Global Infect Dis [serial online] 2020 [cited 2020 Jun 7];12:39-43. Available from: http://www.jgid.org/text.asp?2020/12/2/39/284630




During the past 4 months, we have witnessed unfolding of the COVID-19 pandemic that by now has affected every corner of the planet, infecting more than 3.3 million people, killing more than 234,000,[1],[2] and directly or indirectly affecting billions of individuals.[3] The quick rise in both cases and deaths was due to the high infectivity of the virus, quickly overwhelming health-care systems and prompting physical distancing measures of historically unprecedented scale.[4] The speed and robustness of public health responses within individual countries appear to be associated with early successful containment, fewer cases, and lower mortality.[5],[6] Driven by fears just as powerful as hopes, the humanity is now firmly united in defeating the common enemy, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2).

As country after country fell victim to the relentless disease, disbelief gave way to horror as the “far-away problem” became one that hits all too close to home.[7] One new fact after another emerged about our new mortal enemy – from its ruthless affinity for those with comorbid conditions to the high proportion of asymptomatic or presymptomatic transmission.[4] With few exceptions, there is a striking yet expected relationship between the average recorded daily deaths per million population and both the average age and the percentage of geriatric population among countries around the world [Figure 1]a and [Figure 1]b[8],[9],[10]. There may also be a similar correlation between the number of symptomatic cases and the average population age,[11] suggesting strongly that SARS-CoV-2 does not appear to discriminate by national wealth, per-capita income, or number of hospital beds per person.[11],[12],[13],[14] It is hoped that the costly lessons of what is believed to be only the first global wave of COVID-19 will help inform any subsequent waves of COVID-19 disease, as well as future pandemic response across both high-income countries (HICs) and low-and-middle-income countries (LMICs).[14],[15]
Figure 1: Deaths per million population versus (a, top) mean age of country's population and percentage of country's population ≥65 years (b, bottom)

Click here to view


The collective learning among geographically separated members of the international medical community is another example of the new global age of instant scientific communication and synergy creation. In this context, several group experiences helped change and refine how we treat patients. For example, the initial management approach in Europe and America was to intubate early, when the COVID-19 respiratory failure was still mild.[16],[17],[18] However, this approach did not seem to reduce mortality in the affluent Lombardy region of Italy, where some of the highest mortality rates in the world were recorded.[16] This aggressive intubation approach was contrasted to a study from China where patients with COVID-19 pneumonia were treated with high-flow nasal cannula (HFNC) as the first-line therapy, followed by a stepwise escalation to noninvasive ventilation (NIV) and then tracheal intubation for refractory cases.[19] In the latter experience, only 4 out of 318 patients were eventually intubated.[19] Similar experiences and success stories have been reported with early proning of nonintubated patients.[4],[20]

Recent reports also suggest that many patients with COVID-19 present with so-called “silent hypoxia” that is characterized by the apparent absence of dyspnea or overt air hunger.[21],[22] Of interest, patients with such “silent hypoxia” appear to be more likely to progress on to develop severe respiratory failure of COVID-19 within 2–4 days without early aggressive intervention (e.g., HFNC and nonintubated proning). Mechanistically, the damaged lungs have impaired O2 handling, but the CO2 exchange is still intact. Because CO2 is the main driver for dyspnea, patients may feel falsely reassured and thus do not seek emergent medical attention. Instead, hypoxia is compensated by involuntary tachypnea for 2–4 days while the lung injury progresses, up until a cytokine storm occurs, with ensuing dyspnea, elevated CO2, and the rapid development of severe respiratory failure.[21],[22] From public health perspective, this phenomenon requires early and aggressive implementation of home- or community-based pulse oximetry programs, combined with around-the-clock telemedicine services, to effectively intercept patients who may be entering the rapid deterioration phase of COVID-19.[21],[23],[24],[25]

To help address the impact of “silent hypoxia” in both LMIC and HIC settings, we recommend the following combined public/community health plus hospital based-management approach to decrease the need for invasive ventilation and overall mortality in the event of widespread community transmission:

  1. Approximately 90% of COVID-19 patients do not require hospitalization, and it may be sufficient to isolate mildly symptomatic or asymptomatic cases in their homes for 14–28 days[26]
  2. When continuous pulse oximetry is not available, monitor those showing mild symptoms at least every 8–12 h for “silent hypoxia” – also see ACAIM-WACEM Joint Working Group clinical management algorithm[22]
  3. Public education and increased access to pulse oximetry near-patient homes will be critical to successful remediation of the “silent hypoxia” phenomenon
  4. Once detected, treatment of silent hypoxia (SpO2<90%–93% or respiratory rate >25/min) should be started according to the following stepwise escalation protocol:[22],[27]


    1. Oxygen through nasal prongs or face mask 5–6 L/min
    2. If SpO2 remains <88% on nasal prongs, use nonrebreathing masks 10–15 L/min
    3. If SpO2 remains <88% on non-rebreathing masks, use either NIV or HFNC (depending on availability)
    4. If SpO2 remains <88% on NIV or HFNC, consider invasive ventilation.


  5. Keep patient in prone position alternating with sitting position for >16 h/day or as long as reasonably feasible[4],[28]
  6. Consider restricted use of intravenous fluids and the use of corticosteroids for severe respiratory failure as per recommendations,[17] with appropriate medication including low molecular weight heparin and end-organ support as per prevailing recommendations.


As various hospital and intensive care therapies and management approaches take shape, so does an entire new universe of telemedicine as it comes of age. Following its inception, telehealth was viewed by some as a “modality looking for indications.”[29],[30] This is no longer the case, as the Centers for Medicare and Medicaid Services recently adopted equivalency for tele- and in-person care, voiding the need for the existence of a prior patient–physician relationship to pay claims for telemedicine visits.[31] This is just one way in which the COVID-19 pandemic permanently changed the health-care landscape, with true effects and the magnitude of such tectonic shift to be felt for years to come.[25] In addition to enabling ongoing care of patients with chronic medical conditions, the new paradigm also enables innovative approaches to cross-border specialty expertise sharing as well as continued productive employment of health-care providers who may be under quarantine orders.[4],[25] The current pandemic is likely the beginning of a long-term trend toward sustainable, home-based care models.[30],[32]

As frontline medical personnel make important clinical discoveries and advances, so do basic and translational scientists. Despite multiple clinical studies, from retrospective reviews to prospective randomized trials, showing limited or no efficacy of one therapeutic agent after another, much hope remains as the resilient cycle of scientific discovery ploughs ahead.[4],[33],[34],[35] And although there is no “magic bullet” in sight, several important discoveries were made in the areas of antivirals (preliminary results suggesting that remdesivir may shorten the duration of illness) and vaccines.[36],[37],[38],[39] The first, and somewhat surprising finding, is the association between universal Bacillus Calmette–Guerin (BCG) national vaccination policies and reduced morbidity and mortality among COVID-19 patients.[37] Clinical trials of BCG vaccination among health-care workers are ongoing.[40],[41],[42] The second, and somewhat expected finding, is the apparent efficacy of convalescent plasma in the management of severe COVID-19 infections.[43],[44],[45] A longer-term, sustainable derivative that builds on the theme of convalescent plasma is the identification and synthesis of highly effective anti-SARS-CoV-2 antibodies.[35],[46],[47],[48] Finally, important new developments are emerging in the race to produce an effective human vaccine,[38],[49],[50] although the final product will likely not be available in the immediate future.

In addition to the development of new therapeutics and vaccines, there is a tremendous need for better understanding of the COVID-19 clinical disease. For example, we do not fully understand why the disease seems to take a largely binary course – for some, it appears to be a “flu-like illness,” while for others, it takes a much more acute course. The differentiation between the two “disease paths” seems to be occurring right around the 2nd week of the illness.[51] Still, etiologic factors responsible for this phenomenon remain unknown. In another highly controversial observation, tobacco smokers appeared to be somewhat protected from the more severe manifestations of COVID-19, but it is not clear what factors (or unrecognized biases) may be responsible for these preliminary findings and confirmatory research will be required to substantiate any associated claims.[52],[53] The ongoing recognition of new signs and symptoms, long after the first reported case of COVID-19, exemplifies the diverse number of presentations associated with the viral illness. For example, only recently was the phenomenon of “COVID toes” described,[54] and there is a growing recognition of the association between COVID-19 and thromboembolic phenomena.[55],[56] There is also the spirit of innovation in the face of adversity. For example, when faced with acute shortage of N95 respirator masks and face shields, citizenry around the globe began designing, testing, and making their own substitute do-it-yourself products, with various degrees of success and air filtration effectiveness.[57],[58],[59]

As the global fight against the pandemic continues, we must remember and persist in the hope that this traumatic event will eventually come to an end. With this optimistic outlook, we must start thinking about the humanity's emergence from the state of “deep freeze,” physical distancing, and the respectful fear of the unknown. Key to this post-COVID-19 “rebirth” of sorts will be a well-organized, well-thought-out system of checks and balances that will allow the maintenance of appropriate safety measures while also permitting the return of economic activity in the broadest possible sense. A formidable new challenge will be the copresence of COVID-19 and influenza during the next annual “flu season,” effectively resulting in what the authors are coining as “Covi-Flu season.” The costs of dual testing, personal protective equipment, as well as the need for high degree of clinical vigilance are likely to create significant inefficiencies across our clinics and emergency departments. To overcome this and many other challenges, some degree of “collective sacrifice” will likely be necessary, whether it means large-scale testing and issuing vaccination/immunity certificates, or perhaps a protracted period of continued social distancing with associated ramification of being “together but separated.” Ultimately, these difficult questions will need to be answered by citizens of each region of the globe while maintaining the utmost respect for the prevailing cultural norms, individual freedoms, and the collective societal well-being. We live in special times, and we shall emerge from the great challenge of the COVID-19 pandemic together, as a one human family, stronger, wiser, and better.



 
   References Top

1.
World-O-Meter. COVID-19 Coronavirus Pandemic; 2020. Available from: https://www.worldometers.info/coronavirus/. [Last accessed on 2020 Mar 29].  Back to cited text no. 1
    
2.
World Health Organization. Rolling Updates on Coronavirus Disease (COVID-19). World Health Organization; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. [Last accessed on 2020 Apr 27].  Back to cited text no. 2
    
3.
Gozes O, Frid-Adar M, Greenspan H, Browning PD, Zhang H, Ji W. Rapid ai Development Cycle for the Coronavirus (covid-19) Pandemic: Initial Results for Automated Detection and Patient Monitoring Using Deep Learning ct Image Analysis. arXiv preprint arXiv; 2003.05037, 2020.  Back to cited text no. 3
    
4.
Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, et al. The 2019-2020 Novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group statement. J Global Infect Dis 2020;12:47-93  Back to cited text no. 4
    
5.
Day M. Eastern European Economies Begin to Reopen: Former Eastern Block Nations Appear to have Coped Much Better with the Pandemic than those in Western Europe; 2020. Available from: https://www.telegraph.co.uk/news/2020/04/30/eastern-european- economies-begin-reopen/. [Last accessed on 2020 Apr 30].  Back to cited text no. 5
    
6.
Giugliano F. Greece Shows how to Handle the Crisis: The Government Imposed Severe Social Distancing Measures Much Earlier than Others; 2020. Available from: https://www.bloomberg.com/opinion/articles/2020-04-10/greece- handled-coronavirus-crisis-better-than-italy-and-spain. [Last accessed on 2020 Apr 30].  Back to cited text no. 6
    
7.
Buchan, G. Australia Goes Hard and Goes Early on Covid-19; 2020. Available from: https://www.csis.org/analysis/australia-goes-hard-and-goes-early-covid-19. [Last accessed on 2020 Apr 28].  Back to cited text no. 7
    
8.
Department of Economic and Social Affairs, P.D., United Nations, World Population Prospects; 2019.  Back to cited text no. 8
    
9.
Max Roser HR, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org; 2020.  Back to cited text no. 9
    
10.
Agency CI. The World Factbook 2020; 2020.  Back to cited text no. 10
    
11.
World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports. World Health Organization; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [Last accessed on 2020 Mar 07].  Back to cited text no. 11
    
12.
The World Bank. World Bank Country and Lending Groups; 2020. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. [Last accessed on 2020 Apr 28].  Back to cited text no. 12
    
13.
World Health Organization. Global Health Observatory Data Repository: Hospital Bed Density Data by Country. World Health Organization; 2020. Available from: https://apps.who.int/gho/data/view.main.HS07v. [Last accessed on 2020 Apr 28].  Back to cited text no. 13
    
14.
Harden RD, Ivers LC. Anticipating the Next Waves of COVID-19; 2020. Available from: https://thehill.com/opinion/healthcare/490028-anticipating-the-next-waves-of-covid-19. [Last accessed on 2020 Apr 28].  Back to cited text no. 14
    
15.
Lawton, G. Will the Spread of Covid-19 be Affected by Changing Seasons? 2020. Available from: https://www.newscientist.com/article/2239380-will-the-spread-of-covid-19-be-affected-by-changing- seasons/. [Last accessed on 2020 Apr 28].  Back to cited text no. 15
    
16.
Grasselli G, Zangrillo A, Zanella A, Massimo Antonelli M, Cabrini L, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region. Italy, Jama; 2020.  Back to cited text no. 16
    
17.
Poston JT, Patel BK, Davis AM. Management of Critically Ill Adults with COVID-19. Jama; 2020.  Back to cited text no. 17
    
18.
Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al; Asian Critical Care Clinical Trials Group. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8:506–17.  Back to cited text no. 18
    
19.
Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus -infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care 2020;10:1-5.  Back to cited text no. 19
    
20.
Siow WT, et al. Managing COVID-19 in resource-limited settings: Critical care considerations. Bio Med Cent Crit Care. 2020;24:167.  Back to cited text no. 20
    
21.
Levitan R. The infection that's silently killing coronavirus patients; 2020. Available from: https://www.nytimes.com/2020/04/20/opinion/sunday/coronavirus-testing-pneumonia.html. [Last accessed on 2020 Apr 28].  Back to cited text no. 21
    
22.
Galwankar S, Paladino L, Gaieski DF, Nanayakkara P, DiSomma S, Grover J, et al. Management algorithm for subclinical hypoxemia in COVID-19 patients: Intercepting the 'silent killer. J Emerg Trauma Shock 2020:13; In press.  Back to cited text no. 22
    
23.
Nacoti M, et al. At the epicenter of the Covid-19 pandemic and humanitarian crises in Italy: Changing perspectives on preparation and mitigation. NEJM Catalyst Innovat Care Delivery 2020;1. Catal Non-Issue Content [Internet].  Back to cited text no. 23
    
24.
Wong AW. et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic. Chest. 2020;S0012-3692(20)30756-X.  Back to cited text no. 24
    
25.
Chauhan V, et al. Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission. J Emerg Trauma Shock 2020;13:20.  Back to cited text no. 25
  [Full text]  
26.
Burrer SL, et al. Characteristics of Health Care Personnel with COVID-19-United States, February 12–April 9, 2020; 2020.  Back to cited text no. 26
    
27.
Dondorp AM, et al. Respiratory support in novel coronavirus disease (COVID-19) patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020;10.4269/ajtmh.20-0283.  Back to cited text no. 27
    
28.
Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care 2020;10:1-4.  Back to cited text no. 28
    
29.
John O, Jha V. Remote Patient Management in Peritoneal Dialysis: An Answer to an Unmet Clinical Need, in Remote Patient Management in Peritoneal Dialysis. Karger Publishers; 2019. p. 99-112.  Back to cited text no. 29
    
30.
Wade VA, Taylor AD, Kidd MR, Carati C. Transitioning a home telehealth project into a sustainable, large-scale service: A qualitative study. BMC Health Serv Res 2016;16:183.  Back to cited text no. 30
    
31.
Bini SA, Schilling PL, Patel SP, Kalore NV, Ast M, Maratt J. Digital orthopaedics. A glimpse into the future in the midst of a pandemic. J Arthrop 2020.  Back to cited text no. 31
    
32.
Kamsu-Foguem B, Foguem C. Telemedicine and mobile health with integrative medicine in developing countries. Health Policy Technol 2014;3:264-71.  Back to cited text no. 32
    
33.
Sayburn A. Covid-19: trials of four potential treatments to generate “robust data” of what works. BMJ. 2020 Mar 24;368:m1206.  Back to cited text no. 33
    
34.
Freund A. Coronavirus Studies: Chloroquine is Ineffective and Dangerous; 2020. Available from: https://www.dw.com/en/chloroquine-is-ineffective-and-dangerous/a-53188219. [Last accessed on 2020 Apr 28].  Back to cited text no. 34
    
35.
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP. COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. [published online ahead of print, 2020 Mar 18]. Hum Vaccin Immunother. 2020;1-7.  Back to cited text no. 35
    
36.
Krawczy K. FDA Reportedly Plans to Authorize Emergency use of Largely Untested Drug to Treat Coronavirus; 2020. Available from: https://news.yahoo.com/fda-reportedly-plans-authorize-emergency-190500694.html. [Last accessed on 2020 Apr 30].  Back to cited text no. 36
    
37.
Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study. medRxiv 2020.  Back to cited text no. 37
    
38.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1-9.  Back to cited text no. 38
    
39.
Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12:254.  Back to cited text no. 39
    
40.
ClinicalTrials. Gov. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04327206. [Last accessed on 2020 Apr 05].  Back to cited text no. 40
    
41.
Prestigiacomo A. Vaccine From 1920s Being Tested To Fight Coronavirus; 2020. Available from: https://www.dailywire.com/news/vaccine-from-1920s-being-tested-to-fight-coronavirus. [Last accessed on 2020 Apr 05].  Back to cited text no. 41
    
42.
Mack E. A Vaccine from the 1920s is Now Being Tested for use Against the Coronavirus Pandemic; 2020. Available from: https://www.forbes.com/sites/ericmack/2020/03/31/a-vaccine-from-the-1920s-could-help-fight-the-coronavirus-pandemic/#17a40c3c1220. [Last accessed on 2020 Apr 28].  Back to cited text no. 42
    
43.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama 2020;323: 1582–9.  Back to cited text no. 43
    
44.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceed Natl Acad Sci 2020;117:9490–6.  Back to cited text no. 44
    
45.
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. Published 2020 Mar 26. doi:10.1136/bmj.m1256.  Back to cited text no. 45
    
46.
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38:10-18. doi:10.12932/AP-200220-0773.  Back to cited text no. 46
    
47.
Liu C, Zhou Q, Li Y, Garner L. V Watkins SP, Carter LJ, Smoot J, et al. (2020). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS central science, 6:315–31.  Back to cited text no. 47
    
48.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19 [published online ahead of print, 2020 Mar 5]. J Pharm Anal. 2020.  Back to cited text no. 48
    
49.
Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (2020). The COVID-19 vaccine development landscape. Nature reviews. Drug discovery, 19(5), 305–306.  Back to cited text no. 49
    
50.
Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 Vaccine Pipeline: an Overview [published online ahead of print, 2020 Mar 3]. Curr Trop Med Rep. 2020;1-4.  Back to cited text no. 50
    
51.
Bernstein L, Cha AE. Second-Week Crash' is time of Peril for Some Covid-19 Patients. 2020. Available from: https://www.washingtonpost.com/health/second-week-crash-is-time-of-peril-for-some-covid-19- patients/2020/04/29/3940fee2-8970-11ea-8ac1-bfb250876b7a_story.html. [Last accessed on 2020 Apr 30].  Back to cited text no. 51
    
52.
O'Donnell, T. Scientists are Perplexed by the Low Rate of Coronavirus Hospitalizations Among Smokers. Nicotine May Hold the Answer; 2020. Available from: https://theweek.com/speedreads/911429/scientists-are-perplexed-by-low-rate-coronavirus-hospitalizations- among-smokers-nicotine-may-hold-answer. [Last accessed on 2020 Apr 30].  Back to cited text no. 52
    
53.
Farsalinos K, Barbouni A, Niaura R. Smoking, Vaping and Hospitalization for COVID-19. Qeios; 2020.  Back to cited text no. 53
    
54.
Lee JY. 'COVID toes' Might be the Latest Unusual Sign that People are Infected with the Novel Coronavirus; 2020. Available from: https://www.businessinsider.com/covid-toes-frostbite-coronavirus-skin-lesion-discolored-swollen-feet- 2020-4. [Last accessed on 2020 Apr 30].  Back to cited text no. 54
    
55.
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19 [published online ahead of print, 2020 Apr 17]. J Thromb Haemost. 2020;10.1111/jth.14849.  Back to cited text no. 55
    
56.
Hamilton J. Doctors Link COVID-19 To Potentially Deadly Blood Clots and Strokes; 2020. Available from: https://www.npr.org/sections/health-shots/2020/04/29/847917017/doctors-link-covid-19-to-potentially-deadly-blood-clots-and- strokes. [Last accessed on 2020 Apr 30].  Back to cited text no. 56
    
57.
Berkowitz B, Steckelberg A. Answers to your DIY Face Mask Questions, Including what Material you Should Use; 2020. Available from: https://www.washingtonpost.com/health/2020/04/07/answers-your-diy-face-mask-questions-including-what- material-you-should-use/?arc404=true. [Last accessed on 2020 Apr 30].  Back to cited text no. 57
    
58.
Konda A, Prakash A, Moss GA, Schmoldt M, Grant GD, Guha S. Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. ACS Nano; 2020.  Back to cited text no. 58
    
59.
Toussaint, K. Makers are Rushing to Fight Coronavirus with 3D Printed face Shields and Test Swabs; 2020. Available from: https://www.fastcompany.com/90482710/makers-are-rushing-to-fight-coronavirus-with-3d- printed-face-shields-and-test-swabs. [Last accessed on 2020 Apr 30].  Back to cited text no. 59
    

Top
Correspondence Address:
Dr. Vivek Chauhan
Department of Medicine, IGMC, Shimla, Himachal Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jgid.jgid_96_20

Rights and Permissions


    Figures

  [Figure 1]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed286    
    Printed19    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008